

Iconovo AB changes Certified Adviser to Tapper Partners AB

Iconovo AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.

Iconovo AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser. Tapper Partners AB will assume the role of Certified Adviser on 15 August 2025. Until then, DNB Carnegie Investment Bank AB will continue to act as the company's Certified Adviser.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort®. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

[Iconovo AB changes Certified Adviser to Tapper Partners AB](#)